---
title: "Inebilizumab for AQP4-IgG–Positive NMOSD with Coexisting Autoimmunity: Two Case Reports"
id: "frontiers-in-immunology-17-case-report-inebilizumab-in-aqp4-igg-positive-neuromyelitis-optica-spectrum"
canonical_url: "https://medichelpline.com/clinical-feed/frontiers-in-immunology-17-case-report-inebilizumab-in-aqp4-igg-positive-neuromyelitis-optica-spectrum"
content_type: "clinical_feed_article"
specialty: "Neurology"
source_name: "Frontiers in Immunology"
source_url: "https://www.frontiersin.org/articles/10.3389/fimmu.2026.1984033"
published_at: "2026-11-13T00:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Inebilizumab for AQP4-IgG–Positive NMOSD with Coexisting Autoimmunity: Two Case Reports
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/frontiers-in-immunology-17-case-report-inebilizumab-in-aqp4-igg-positive-neuromyelitis-optica-spectrum
- **Specialty:** [Neurology](https://medichelpline.com/clinical-feed/neurology.md)
- **Primary Source:** Frontiers in Immunology
- **Source URL:** [Original Journal Publication](https://www.frontiersin.org/articles/10.3389/fimmu.2026.1984033)
- **Published At:** 2026-11-13T00:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- Two AQP4-IgG–positive patients with overlapping autoimmune features received **inebilizumab** and demonstrated marked clinical improvement without recorded relapse to date. - Case 1: 29-year-old woman presented with area postrema syndrome (persistent hiccups, dysphagia), dorsal medullary lesion on MRI, positive anti-AQP4 IgG (1:100), and serological markers suggesting a lupus-like phenotype; initial corticosteroid course was limited then escalated, followed by two 300 mg infusions of **inebilizumab** with rapid symptom resolution and EDSS improvement from 4 to 0. - Case 2: Patient with established, clinically stable NMOSD later developed acetylcholine receptor (AChR)–IgG–positive generalized **myasthenia gravis**; after **inebilizumab** therapy the authors reported clinical benefit and reduction in CD19+ B cells. - Laboratory response in Case 1 included a substantial post-treatment decline in CD19+ B-cell counts and a fall in anti-AQP4 antibody titer on follow-up testing; MRI showed progressive regression of the dorsal medullary lesion. - Investigators reported no relapses and favorable tolerability during follow-up. - The report underlines the potential role of **inebilizumab** for AQP4-IgG–seropositive **NMOSD**, including presentations with area postrema syndrome or coexisting autoimmune disease such as **SLE** or **MG**, but acknowledges limited sample size and need for prospective data on overlap phenotypes and steroid-sparing strategies.
## Clinical Analysis & Structured Key Points
Frontiers | Case Report: Inebilizumab in AQP4-IgG-positive neuromyelitis optica spectrum disorder with autoimmune diseases: a case series of two patients CASE REPORT article Front. Immunol. , 13 November 2026 Sec. Autoimmune Disorders Volume 17 - 2026 | https://doi.org/10.3389/fimmu.2026.1984033 Published in Frontiers in Immunology Autoimmune Disorders 7 impact factor 11.3 citescore Editor & Reviewers Edited by L A Luis Alberto Ponce-Soto Reviewed by K T KONSTANTINOS TSAFIS N A Nabil Akkawi Outline Figures and Tables Figure 1 View in article Figure 2 View in article Figure 3 View in article Table 1 Laboratory and antibody findings in Case 1 and Case 2. View in article CASE REPORT article Front. Immunol. , 13 November 2026 Sec. Autoimmune Disorders Volume 17 - 2026 | https://doi.org/10.3389/fimmu.2026.1984033 Case Report: Inebilizumab in AQP4-IgG-positive neuromyelitis optica spectrum disorder with autoimmune diseases: a case series of two patients H M Houying Mu 1 † H D Hai Du 2,3 † X D Xian-Bo Deng 4 Z F Zhi Fang 1 Z S Zhou Sun 1 Z W Zuo-Tian Wu 1 L Z Lei Zhang 1 L L Liu L. Yang 1 * Y X Yuanpeng Xia 1 * 1. Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China 2. Department of Hand Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China 3. Department of Neurology, Union Jiangbei Hospital, Huazhong University of Science and Technology, Wuhan, China 4. Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China See more Article metrics View details Abstract Background: Neuromyelitis optica spectrum disorder (NMOSD) is a rare spectrum autoimmune disease of the central nervous system, primarily characterized by recurrent episodes of severe optic neuritis and myelitis. Area postrema syndrome (APS) is a common manifestation of NMOSD that is often misdiagnosed initially. Myasthenia gravis (MG) is another uncommon autoimmune disease that occasionally coexists with NMOSD. To date, there are no approved therapies specifically for NMOSD coexists with autoimmune disease. Inebilizumab is a humanized anti-CD19 monoclonal antibody used to treat autoimmune diseases associated with CD19-positive B cells. The first global approval of inebilizumab for the treatment of adult patients with aquaporin-4 antibody (AQP4)-IgG-seropositive NMOSD was announced in June 2020. Case presentation: We present two patients with AQP4-IgG-positive NMOSD and coexisting autoimmune disease. One patient presented with APS and coexisting systemic lupus erythematosus (SLE), and the other had established, clinically stable NMOSD and newly diagnosed acetylcholine receptor (AChR)-IgG-positive generalized MG. Both patients showed significant clinical improvement following treatment with inebilizumab, and no relapse has been recorded to date. Conclusion: The two cases highlight the potential efficacy of inebilizumab in the treatment of NMOSD. The findings suggest that inebilizumab may be an effective therapeutic option for patients with NMOSD, particularly those who are seropositive for AQP4-IgG or have coexisting autoimmune diseases. 1 Introduction Neuromyelitis optica spectrum disorder (NMOSD) is a rare, relapsing autoimmune astrocytopathy of the central nervous system, primarily characterized by recurrent episodes of severe optic neuritis and longitudinally extensive transverse myelitis with secondary demyelination and axonal injury ( 1 , 2 ). The incidence and prevalence of NMOSD vary substantially across geographic regions and populations. A global systematic review reported annual incidence rates ranging from 0.039 to 0.73 per 100, 000 person-years among adults ( 3 ), whereas a national population-based study in China estimated an age- and sex-adjusted annual incidence of 0.278 per 100, 000 person-years ( 4 ). Aquaporin-4 (AQP4)- immunoglobulin G (IgG)-seropositive NMOSD shows a marked female predominance, with reported female-to-male ratios of up to 9:1, and the mean age at disease onset is approximately 40 years ( 2 ). The pathogenesis of NMOSD is driven by autoantibodies targeting AQP4, a water channel protein highly expressed on astrocytic end-feet in the central nervous system. AQP4-IgG-positive NMOSD is primarily an autoimmune astrocytopathy that leads to loss of AQP4 expression, complement deposition, astrocyte injury, neuroinflammation, and subsequent secondary demyelination and axonal damage ( 2 , 5 – 8 ). The infiltration of granulocytes, macrophages, and activated microglia further exacerbates tissue damage, resulting in the characteristic clinical manifestations of NMOSD ( 2 , 6 , 9 ). Characteristic magnetic resonance imaging (MRI) patterns include longitudinally extensive transverse myelitis involving three or more contiguous vertebral segments, posterior optic nerve lesions that may extend to the optic chiasm, and dorsal medullary lesions involving the area postrema. Direct comparison with previous MRI examinations is important for distinguishing newly active lesions from residual structural abnormalities. Recent research has also highlighted the role of innate immune dynamics, including neutrophil extracellular traps and tissue-resident memory T cells, in lesion expansion and relapse triggering ( 10 ). Clinical manifestations of NMOSD vary depending on the affected anatomical structures. Six core syndromes have been established, involving the optic nerve, spinal cord, area postrema, brainstem, diencephalon, and cerebral cortex ( 1 , 2 ). The most common presentations are optic neuritis, transverse myelitis, and area postrema syndrome (APS) ( 2 ), which manifests as intractable hiccups, nausea, and vomiting. APS can appear as an isolated symptom in approximately 12% of early-stage NMOSD cases, making it prone to misdiagnosis ( 11 ). As an autoimmune disorder, approximately one-quarter of patients with AQP4-IgG-seropositive NMOSD have concomitant autoimmune diseases, most commonly systemic lupus erythematosus and Sjögren’s syndrome, rheumatoid arthritis has also been reported ( 2 , 12 ). Small-sample studies have also documented the co-occurrence of NMOSD and myasthenia gravis (MG). McKeon et al.’s case-control study of 177 patients with NMOSD reported that 2% had MG, while muscle-type acetylcholine receptor (AChR) antibodies were detected in 11% of the entire NMOSD cohort ( 13 ). To date, acute NMOSD attacks are empirically managed with intravenous methylprednisolone (IVMP) as first-line therapy, along with plasma exchange, intravenous immunoglobulin (IVIG), and immunoadsorption (IA) ( 14 ). However, only approximately 17% of patients achieve complete remission after initial steroid treatment, and 16% show no improvement ( 15 ). For long-term relapse prevention, conventional immunosuppressive treatments have included oral glucocorticoids, azathioprine, and mycophenolate mofetil, while rituximab has been widely used as an off-label B-cell-depleting therapy ( 14 ). These treatments can reduce relapse activity but have limitations, including delayed onset of action, variable efficacy, cumulative toxicity, and limited evidence from controlled trials. Without effective acute and preventive treatment, about 50% of NMOSD patients become wheelchair-dependent or severe visual impairment, and about 1/3 of patients die within five years of onset ( 16 ). The therapeutic landscape for NMOSD has been transformed by the approval of targeted monoclonal antibodies, including inebilizumab, eculizumab, satralizumab, and ravulizumab ( 14 , 17 ). In a small open-label randomized trial involving 68 patients who completed 12 months of follow-up, both azathioprine and rituximab reduced the annualized relapse rate and Expanded Disability Status Scale (EDSS) score, while rituximab was associated with a greater reduction in relapse activity and a higher proportion of relapse-free patients than azathioprine. However, the open-label design, small sample size, short follow-up, and inclusion of both AQP4-IgG-positive and seronegative patients limit the generalizability of these findings. Current Neuromyelitis Optica Study Group (NEMOS) recommendations consider conventional immunosuppressive treatments less effective than biological therapies, although patients who remain stable and tolerate these agents do not necessarily need to switch treatment ( 18 ). Inebilizumab is a humanized afucosylated IgG1 monoclonal antibody that binds to CD19 on B-cell surfaces, promoting antibody-dependent cell-mediated cytotoxicity and B-cell depletion ( 17 ). The pivotal phase 2/3 N-MOmentum trial (N = 230) demonstrated that inebilizumab reduced the risk of NMOSD attack by 73% compared with placebo, with an 86% relative reduction in AQP4-IgG-seropositive patient ( 19 ). In June 2020, inebilizumab received its first global approval in the United States for the treatment of AQP4-IgG seropositive adult NMOSD ( 20 ). Recent research has further shown that inebilizumab reduces serum glial fibrillary acidic protein (GFAP) levels-a biomarker of astrocyte injury-suggesting potential neuroprotective effects beyond relapse prevention ( 21 ). Ongoing studies are evaluating the optimal timing of inebilizumab initiation during acute attacks and its steroid-sparing potential in treatment-naive patients. Despite the established efficacy of inebilizumab in AQP4-IgG-seropositive NMOSD, its therapeutic potential in other antibody-mediated neurological conditions-such as acute inflammatory demyelinating polyneuropathy (AIDP) and myasthenia gravis (MG) remains understudied and requires further exploration, with only scattered preclinical or limited clinical data available to date ( 19 , 22 , 23 ). The unresolved question is its use in the specific NMOSD-MG overlap phenotype, not its efficacy in generalized MG overall. Moreover, two specific clinical challenges warrant attention. First, APS, manifesting as intractable hiccups and vomiting, appears as an isolated early symptom in 12% of NMOSD cases but is frequently misdiagnosed as gastrointestinal disorders, delaying life-saving immunotherapy ( 2 , 24 ). NMOSD may also coexist with systemic lupus erythematosus (SLE), particularly in AQP4-IgG-seropositive patients, complicating the attribution of neurological symptoms and the selection of immunotherapy. Second, the rare co-occurrence of NMOSD and MG creates therapeutic conflicts: corticosteroids may exacerbate MG, while some immunosuppressants used in MG have limited efficacy against NMOSD attacks, and no consensus exists on combination therapy ( 22 , 25 ). In this report, we describe two distinct yet instructive cases: one patient with isolated APS as the initial presentation of NMOSD, and another with concurrent NMOSD and MG. Both patients exhibited marked clinical improvement following inebilizumab administration, with favorable safety profiles. These observations not only underscore the potential expansion of inebilizumab’s indications beyond NMOSD but also highlight the importance of individualized immunotherapy in overlapping autoimmune conditions. We present these cases to contribute real-world evidence to the limited literature and to encourage prospective investigations into the broader applications. 2 Case presentation 2.1 Case 1: NMOSD with APS and coexisting SLE A 29-year-old female patient was admitted to our neurology ward on October 26, 2024, with a 20-day history of recurrent and progressively worsening hiccups, accompanied by dysphagia for 3 days. Meanwhile, the patient also reported dizziness, fever, and expectoration. Her obstetric history was notable for an uncomplicated full-term vaginal delivery three months prior to admission, and she had known allergies to penicillin and cephalosporins. Initial laboratory tests revealed elevated white blood cell count (10.63×10 9 /L), neutrophil count (8.60×10 9 /L), C-reactive protein (CRP, 150 mg/L), erythrocyte sedimentation rate (ESR, 64 mm/h), alanine aminotransferase (ALT, 74 U/L), and D-dimer (1.85 mg/L). Antinuclear antibody testing showed an abnormal titer of 1:1000, with anti-SS-A antibody >8.0, and anti-Ro-52 antibody >8.0 (see Supplementary Table 1 ). Because of the strongly positive antinuclear antibody, anti-SSA antibody, and anti-Ro52 antibody results, the patient was evaluated by the rheumatology team. She had no malar or photosensitive rash, alopecia, oral ulcers, sicca symptoms, inflammatory arthritis, skin tightening, Raynaud phenomenon, or other specific clinical manifestations suggestive of systemic lupus erythematosus. The rheumatological assessment therefore supported seropositive systemic autoimmune disease without overt clinical SLE manifestations, also referred to as a lupus-like or serological lupus phenotype. Hydroxychloroquine was initiated under rheumatological guidance. The relevant consultation record and serological findings are provided in Supplementary Figure 1 and Supplementary Table 1 . Given the concomitant fever, expectoration, and elevated inflammatory markers, empirical antibiotic therapy was initiated for a suspected respiratory tract infection. Conventional MRI of the head and neck revealed an abnormal signal in the medulla oblongata, suggestive of a demyelinating process ( Figure 1A ). Figure 1 Serial brain MRI findings in Case 1. Axial T1-weighted, sagittal T2-weighted, and axial T2-FLAIR images obtained on October 26, 2024 (A) , November 27, 2024 (B) , and May 22, 2025 (C) , showing progressive regression of the dorsal medullary lesion after treatment. The red arrows indicate the lesions. T1WI, T1-weighted imaging; T2WI, T2-weighted imaging; FLAIR, fluid-attenuated inversion recovery. To further characterize the lesion, a lumbar puncture was performed on the second hospital day. Cerebrospinal fluid (CSF) analysis demonstrated elevated microalbumin, immunoglobulin G, and immunoglobulin A levels. Serum testing for central nervous system demyelinating antibodies returned positive for anti-AQP4 IgG at a titer of 1:100 ( Table 1A ; Supplementary Figure 2 ). Furthermore, negative neostigmine test, electromyography (EMG), repetitive electrical stimulation, and acetylcholine receptor (AChR) antibody test results provided no supportive evidence for MG in this clinical context; however, these negative findings alone could not definitively exclude MG. Based on the clinical presentation, MRI findings, and positive AQP4 IgG serology, the patient was diagnosed with APS as a manifestation of NMOSD, with an initial EDSS score of 4, primarily attributable to impaired swallowing function ( Figure 2A ). Table 1 A. Case 1: Cerebrospinal fluid, CNS demyelinating antibodies, and lymphocyte subsets Test Result Reference range (units) 2024/10/26 2024/11/20 2025/5/22 Pressure 120 — 115 80–180 (mmH 2 O) Cell count 3.0 — 1.0 (*10 6 /L) White cell count 3 — 1 (*10 6 /L) Protein 0.48↑ — 0.46↑ 0.15–0.45 (g/L) Glucose 3.24 — 3.47 2.2–3.9 (mmol/L) Chloride 125.1 — 121.2 118–132 (mmol/L) Lactate dehydrogenase (LDH) 15 — 17 — Adenosine deaminase (ADA) 1 — 1 0–12 (U/L) Microalbumin 321.0↑ — 313.0↑ 139–246 (mg/L) CSF immunoglobulin G 73.80↑ — 63.60↑ 4.8–58.6 (mg/L) CSF immunoglobulin M 2.04 — 1.6 0–7 (mg/L) CSF immunoglobulin A 13.90↑ — 7.45↑ 0–7 (mg/L) CNS demyelinating antibody panel Anti-AQP4-IgG 1:100 — 1:10 Negative Anti-MOG-IgG Negative — Negative Negative Anti-GFAP-IgG Negative — Negative Negative Lymphocyte subset analysis (flow cytometry) CD19+ cells as a percentage of lymphocytes — 19.50↑ 9.46 5.0–18.0 (%) Absolute CD19+ cell count — 671.21↑ 180.23 90–560 (cells/μL) B. Case 2: Lymphocyte subsets and antibody tests Test Result Reference range (units) 2024/11/29 2025/7/13 Lymphocyte subset CD19+ cells as a percentage of lymphocytes 9.50 0.43↓ 5.0–18.0 (%) Absolute CD19+ cell count 478.21 5.78↓ 90–560 (cells/μL) CNS demyelinating antibody panel Anti-AQP4-IgG 1:32 1:3200 Negative Anti-MBP-IgG Negative Negative Negative Anti-MOG-IgG Negative Negative Negative MG antibody panel Anti-AChR-IgG 6.107 3.144 <0.5 (nmol/L) Anti-MuSK-IgG <0.001 0.009 ≤0.05 (nmol/L) Anti-Titin-IgG 0.080 0.093 <1 Laboratory and antibody findings in Case 1 and Case 2. (A) Cerebrospinal fluid, antibody, and lymphocyte-subset findings in Case 1. Lumbar punctures were performed on October 26, 2024, and May 22, 2025. (B) Serial lymphocyte subset and antibody findings in Case 2. ↑ and ↓ indicate values above and below the reference range, respectively. AChR, acetylcholine receptor; ALT, alanine aminotransferase; AQP4, aquaporin-4; AST, aspartate aminotransferase; CNS, central nervous system; CSF, cerebrospinal fluid; GFAP, glial fibrillary acidic protein; MBP, myelin basic protein; MG, myasthenia gravis; MOG, myelin oligodendrocyte glycoprotein; MuSK, muscle-specific kinase. Figure 2 Clinical courses, treatments, and longitudinal scores in the two patients. (A) Clinical events and treatments in Case 1, with EDSS scores during treatment and follow-up from October 2024 to May 2025. (B) Clinical events and treatments in Case 2 from NMOSD onset in 2018 through September 2026, with MG-ADL and QMG scores beginning at the assessment for newly symptomatic MG on November 28, 2024. Clinical events and treatments are shown in the upper timelines, and scores are plotted below. Blue diamonds indicate EDSS scores in (A) and QMG scores in (B) ; orange squares indicate MG-ADL scores in (B) Lines connect recorded assessments and do not represent continuous measurements. AChR, acetylcholine receptor; AQP4, aquaporin-4; APS, area postrema syndrome; EDSS, Expanded Disability Status Scale; IgG, immunoglobulin G; IVIG, intravenous immunoglobulin; MG, myasthenia gravis; MG-ADL, Myasthenia Gravis Activities of Daily Living; MGFA, Myasthenia Gravis Foundation of America; MRI, magnetic resonance imaging; NMOSD, neuromyelitis optica spectrum disorder; QMG, Quantitative Myasthenia Gravis; SLE, systemic lupus erythematosus. A standard intravenous corticosteroid regimen with 1000mg/day methylprednisolone was suggested, but the 29-year-old female patient declined because of concern about side effects. Dexamethasone 10 mg/day was therefore used for 5 days. However, her symptoms showed no significant improvement and her EDSS score remained at 4 ( Figure 2A ). The regimen was therefore escalated to methylprednisolone 500 mg/day combined with IVIG 18 g/day (0.4g/Kg/d, 45kg) for 5 days. By November 7, 2024, her symptoms had partially improved, the EDSS score decreased to 2 ( Figure 2A ). Upon discharge, corticosteroids were switched to oral administration with a tapering schedule. On November 20, 2024, the patient was re-admitted because her symptoms-particularly dysphagia- had not fully resolved and continued to affect her daily life. Repeat laboratory tests at this time showed normalized white blood cell count (7.17×10 9 /L), neutrophil count (3.11×10 9 /L), CRP (0.28 mg/L), ESR (15 mm/h) ( Supplementary Table 1 ). Given the suboptimal response to corticosteroids and IVIG, alternative therapy with inebilizumab was recommended. After obtaining informed consent, pre-treatment screening was performed, including assessments for hepatitis B virus, tuberculosis, serum immunoglobulin quantification, and lymphocyte subset analysis. CD19 + cells accounted for 19.50% of the lymphocyte population, with an absolute count of 671.21 cells/μL. No contraindications were identified. The patient received her first dose of inebilizumab (300 mg, intravenous infusion) on November 22, 2024, followed by a second 300-mg dose on December 5, 2024, according to the standard two-dose induction regimen. Her symptoms improved markedly, with no impact on daily activities, and her EDSS score decreased to 0 (assessed on the 5th day after the first dose, on November 27, 2024). Follow-up lymphocyte subset analysis and anti-AQP4 antibody testing demonstrated a substantial reduction in CD19 + B-cell counts ( Table 1A ) and serum anti-AQ
## Related Clinical Research

- [Mycophenolate mofetil for refractory acute-onset CIDP in rheumatoid arthritis: case report overview](https://medichelpline.com/clinical-feed/frontiers-in-immunology-16-mycophenolate-mofetil-as-salvage-therapy-for-refractory-acute-onset-cidp.md)
- [Unable to Access CMAJ Practice Article on Rheumatoid Arthritis — Source Blocked](https://medichelpline.com/clinical-feed/cmaj-2-rheumatoid-arthritis-practice.md)
- [Guideline differences in rheumatoid arthritis-associated interstitial lung disease care](https://medichelpline.com/clinical-feed/pubmed-42888356.md) (DOI: 10.1007/s00296-026-06322-x)
- [Frontiers in Immunology article page — article content not available](https://medichelpline.com/clinical-feed/frontiers-in-immunology-10-integrative-transcriptomics-metabolomics-reveals-sphingolipid-metabolic.md)
- [COVID-19 Burden in Adults with Systemic Autoimmune Rheumatic Diseases in Quebec, 2020–2023](https://medichelpline.com/clinical-feed/medrxiv-15-comparative-burden-of-covid-19-in-adults-with-rheumatic-diseases-and.md)

## Navigation
- [← Back to Neurology Feed](https://medichelpline.com/clinical-feed/neurology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.